Trial summaries, mechanism explainers, safety reviews and pharmacy-regulation guides — sourced to the primary literature and reviewed by a physician.
The dual-receptor mechanism, in plain English.
The lesser-known incretin behind tirzepatide's design.
Half-life, albumin binding and why one weekly shot works.
How it slows the gut and quiets hunger signals.
The science of dose escalation and tolerability.
Mechanism and outcome differences, fairly framed.
From GLP-1 to dual and triple agonists.
Up to ~20.9% mean weight reduction without diabetes.
Weight loss in a harder-to-treat population.
Adding tirzepatide after intensive lifestyle change.
What happens to weight when you stop.
The head-to-head diabetes trial.
The diabetes program behind Mounjaro.
Reducing sleep-apnea severity via weight loss.
Fewer events in obesity-related HFpEF.
Biopsy-confirmed improvement in liver disease.
Nausea, diarrhea and how they're reduced.
A practical, evidence-informed playbook.
The boxed warning and who must avoid it.
What the evidence shows, and the red flags.
Low alone; higher with insulin or sulfonylureas.
Protecting muscle during weight loss.
The biology of why regain is common.
Cardiometabolic markers tend to improve.
Risk markers, SURPASS-CVOT and the caveats.
Delaying type 2 diabetes in high-risk people.
Two pathways, two levels of oversight.
How compounded can differ from the brand.
Subcutaneous basics and cold-chain handling.